Type 2 diabetes mellitus is a common disorder that affects approximately 5% of the population worldwide, especially in industrialized countries (6). Affected patients are usually obese with accumulation of lipids in non-adipose tissues such as the pancreatic islets, liver, heart, skeletal muscle, and blood vessels (7-9). This is associated with impaired glucose-stimulated insulin secretion, increased hepatic glucose production, peripheral insulin resistance, and late complications in various organs (10,11). The ultimate precipitating process responsible for the development of type 2 diabetes is the failure of the pancreatic β-cells to compensate for insulin resistance (7,10,11). However, the mechanism by which the β-cells become unable to meet increased insulin demands remains to be established.
accumulation in non-adipocytes, thereby protecting them from lipotoxicity (7, 9) .
Infusion of recombinant leptin reverses insulin resistance and hyperglycemia in the transgenic model of congenital generalized lipodystrophy and in ob/ob mice (13) .
Adenovirus-mediated hyperleptinemia also decreases the expression of SREBP-1c and lipogenic genes in liver and islets of wild-type fa/fa rats (12) . Leptin also prevents the SREBP-1c overexpression in IRS-2-null mice (15) . It is noteworthy that metformin, an oral anti-hyperglycemic agent, also corrects fatty liver disease in ob/ob mice by inhibition of obesity-related induction of SREBP-1c (14) . The inhibitory effects of metformin on hepatic SREBP-1c expression involves activation of AMPactivated protein kinase (17) . Similarly, Troglitazone, an antidiabetic agent and a high-affinity ligand for the PPAR-γ, prevents SREBP-1c overexpression in ZDF rats (12) . In addition, it has recently been reported that adenovirus-mediated overexpression of SREBP-1c in MIN6 cells results in impaired glucose-stimulated insulin secretion (18) . Therefore, these studies suggest that overexpression of SREBP-1c may be the cause of both liver steatosis and islet β-cell dysfunction.
The present study is designed to evaluate the direct correlation between SREBP-1c overexpression and β-cell dysfunction and to elucidate the underlying molecular mechanism. The Tet-On system was employed in INS-1 cells to achieve tightly controlled and inducible expression of a nuclear active form of SREBP-1c (naSREBP-1c; N-terminal 1-403 amino acids) (19) . Quantification of the gene expression profile in this INS-1 stable cell line revealed that naSREBP-1c induced β-cell dysfunction by targeting multiple genes implicated in carbohydrate metabolism, lipid biosythesis, cell growth, and eventually apoptosis.
EXPERIMENTAL PROCEDURES

Establishment of INS-1 cells permitting inducible expression of naSREBP-1c-Rat
insulinoma INS-1 cell-derived clones were cultured in RPMI1640 containing 11.2 mM glucose (20) , unless otherwise indicated. The first step stable clone INS-rβ cell line, which carries the reverse tetracycline/doxycycline-dependent transactivator (21) was described previously (22, 23) . The plasmid used in the secondary stable transfection were constructed by subcloning the cDNA encoding the nuclear active form of SREBP-1c (naSREBP-1c/ADD1 1-403 (19) , kindly supplied by Dr. B.M. Spiegelman) into the expression vector PUHD10-3 (21) (a generous gift from Dr. H. Bujard). The procedures for stable transfection, clone selection, and screening were described previously (22) .
Immunofluorescence and Western blotting-For immunofluorescence, cells grown on
polyornithine treated glass coverslips were treated for 24 h with or without 500 ng/ml doxycycline. Cells were then washed, fixed in 4% paraformaldehyde, permeabilized with 0.1% Triton X-100 in phosphate-buffered saline containing 1% BSA (PBS-BSA). The preparation was then blocked with PBS-BSA before incubating with the first antibody, anti-SREBP-1 (Santa Cruz, Basel, Switzerland) (1:100 dilution), followed by the second antibody labeling.
For Western blotting cells were cultured with 0, 75, 150, and 500 ng/ml doxycycline for 24 h. Rat islets were isolated by collagenase digestion as described (24) and their nuclear proteins were extracted as previously reported (25) . Total cell proteins were prepared by lysis and sonication of naSREBP-1c # 233 and INS-1E cells in buffer containing 20 mM Tris.HCl, pH 7.4, 2 mM EDTA, 2 mM EGTA, 1% Triton X-100, and 1 mM PMSF. Nuclear extracts and total cellular proteins were fractionated by 9% SDS-PAGE. The dilution for SREBP-1 antibody is 1:1,000. Immunoblotting procedures were performed as described previously (26) using enhanced chemiluminescence (Pierce, Rockford, Illinois) for detection.
Staining of lipid accumulation by Oil Red O and measurements of triglyceride
content-Cells were cultured with 0, 75, 150, and 500 ng/ml doxycycline for 24 h.
Cells were fixed and stained as previously reported (19) . Lipid droplets were visualized using phase-contrast microscopy (Nikon Diaphot). Cellular triglyceride content was determined using Triglyceride (GPO-TRINDER) kit (Sigma, Buchs, Switzerland) according to the manufacturer's protocol. Krebs-Ringer-Bicarbonate-HEPES buffer (KRBH, 140 mM NaCl, 3.6 mM KCl, 0.5 mM NaH 2 PO 4 , 0.5 mM MgSO 4 , 1.5 mM CaCl 2 , 2 mM NaHCO 3 , 10 mM HEPES, 0.1% BSA) containing indicated concentrations of glucose. Insulin content was determined after extraction with acid ethanol following the procedures of Wang et al. (26) . Insulin was detected by radioimmunoassay using rat insulin as a standard (26) .
Measurements of Insulin Secretion and Cellular Insulin
Total RNA Isolation and Northern Blotting-Cells were cultured with or without 500 ng/ml doxycycline in 2.5 mM glucose medium for 16 h, and then incubated for further 6 8 h at 2.5, 6, 12, and 24 mM glucose concentrations. Alternatively, naSREBP-1c # 233 cells were cultured with or without 75 ng/ml doxycycline in standard medium (11.2 mM glucose) for 0, 24, 48, and 96 h. Total RNA was extracted and blotted to nylon membranes as described previously (27) . The membrane was prehybridized and then hybridized to 32 P-labeled random primer cDNA probes according to Wang and Iynedijian (27) . To ensure equal RNA loading and even transfer, all membranes were stripped and re-hybridized with a "house-keeping gene" probe cyclophilin. cDNA fragments used as probes for SREBP-1c, Hnf1α, Hnf4α, glucokinase, Glut-2, insulin, Sur1, Kir6.2, and Pdx1 mRNA detection were digested from the corresponding plasmids. cDNA probes for rat islet amyloid polypeptide (IAPP), Nkx6. 
RESULTS
Establishment of a stable INS
Induction of naSREBP-1c impairs nutrient-stimulated insulin secretion-Induction of
naSREBP1c with 500 ng/ ml doxycycline for 24 h (Fig. 3A) or 75 ng/ml doxycycline for 96 h ( Fig. 4A & B) . Glucokinase is the rate-limiting enzyme for glycolysis and thereby determines β-cell glucose sensing (22, 31) . The effect of naSEBP-1c on β-glucokinase expression is opposite to its action on liver-glucokinase, which is transcribed from a distinct liver-specific promoter (5,32). UCP-2 may act as a protonophore and dissipate the mitochondrial membrane potential, thereby uncoupling respiration from ATP synthesis (33) (34) (35) (36) .
Induction of naSREBP1c also suppressed the expression of pancreas duodenum homeobox (Pdx)-1, hepatocyte nuclear factor (HNF)-4α, and CCAAT/enhancerbinding protein (C/EBP)-β in a dose-and time-dependent manner ( Fig. 4C & D) . The HNF-1α expression was unaffected, whereas the mRNA level of a β-cell transcription factor Nkx6.1 was increased by naSREBP-1c ( Fig. 4C & D) . High-level induction of naSREBP-1c also decreased the transcript levels of insulin and islet amyloid polypeptide (Fig. 4C) . Furthermore, hyperglycemia in animal models of diabetes causes increased SREBP-1 maturation and renal lipid accumulation leading to diabetic nephropathy (50 (Fig. 7C) . In contrast, free fatty acids were without effects (Fig. 7C) . The level of the mature form of SREBP-1 in INS-1E cells treated with high glucose for 48 h is approximately 10% of that of the endogenous precursor protein (Fig. 7C) . This corresponds to the induction observed with 75 ng/ml doxycycline in naSREBP-1c # 233 cells (Fig. 1B) .
Induction of naSREBP-1c disrupts mitochondrial membrane potential-Mitochondrial
DISCUSSION
Intracellular lipid accumulation, termed lipotoxicity (metabolic syndrome X), in skeletal muscle, myocardium, blood vessels, kidney, liver, and pancreatic islets has been speculated to cause, respectively, insulin resistance, cardiac dysfunction, vascular complications, nephropathy, fatty liver (hepatic steatosis), and β-cell dysfunction in Type 2 diabetes (9,50). However the molecular mechanism underlying the pathogenesis of lipotoxicity in pancreatic β-cells and other non-adipose tissues remain undefined. In fact, lipotoxicity is a confusing concept. Some investigators refer to lipotoxicity as the consequence of increased circulating free acids and cellular lipid accumulation (7-9), whereas others suggest that glucotoxicity is the prereqisite for lipotoxicity, at least in β-cells (58, 59, (65) (66) (67) (68) . The present study and our unpublished data support the latter (see bellow). In creased expression of has been demonstrated in islets and/or liver in several animal models of diabetes (7, (12) (13) (14) (15) (16) . Overexpression of SREBP-1 has been suggested to be the cause of hepatic steatosis (14, 16, 51, 53, 69, 70) and diabetic nephropathy (50) . The present study provides direct and strong evidence proving that the transcriptional activity of SREBP-1c also mediates β-cell dysfunction. In addition, the present study also suggests that, in contrast to hepatocytes and 
